These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12510655)

  • 1. Triple PI therapy--perhaps more is not better.
    Jenny-Avital ER
    AIDS Clin Care; 2002 Dec; 14(12):105-6. PubMed ID: 12510655
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelfinavir combination therapy: ten-month report.
    AIDS Treat News; 1997 Apr; (No 269):3. PubMed ID: 11364253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 5. A controlled trial of double versus triple therapy for HIV.
    Delgado Fernández M; Zambrana García JL; Díez García F
    N Engl J Med; 1998 Jan; 338(3):197. PubMed ID: 9441226
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiretroviral rounds. Putting resistance to work.
    Daar ES; Elion R
    AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
    [No Abstract]   [Full Text] [Related]  

  • 7. [Administer a protease inhibitor immediately? Proceeding strategically in HIV therapy].
    MMW Fortschr Med; 2000; 142(3 Suppl):6-7. PubMed ID: 10893947
    [No Abstract]   [Full Text] [Related]  

  • 8. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
    Portilla J; Boix V; Garcia-Henarejos JA; Llopis C; Martínez-Madrid O; Gimeno A; Sánchez-Paya J; Merino E
    Int J STD AIDS; 2005 Dec; 16(12):807-10. PubMed ID: 16336763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Observing CD4 cell count and viral load alone is not enough. Value of protease inhibitors].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():81-2. PubMed ID: 10863321
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.
    Jeremy RJ; Kim S; Nozyce M; Nachman S; McIntosh K; Pelton SI; Yogev R; Wiznia A; Johnson GM; Krogstad P; Stanley K;
    Pediatrics; 2005 Feb; 115(2):380-7. PubMed ID: 15687448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract]   [Full Text] [Related]  

  • 13. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [First-line monotherapy with boostered protease inhibitor. Effectively reduce viral load with only one drug?].
    Theobald T; Jäger H
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():28-9. PubMed ID: 16385867
    [No Abstract]   [Full Text] [Related]  

  • 15. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy.
    Coll B; Alonso-Villaverde C; Parra S; Rabassa A; Martorell L; Joven J; Masana L
    HIV Med; 2006 Sep; 7(6):356-60. PubMed ID: 16903979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV agents. Promising results from a saquinavir study.
    TreatmentUpdate; 2007 Jan; 19(1):9-10. PubMed ID: 17390482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.